New research identifying molecular biomarkers predictive of radiosensitivity in adult gliomas aims to refine radiotherapy strategies for these aggressive brain tumors. Given glioma’s notorious resistance to radiation, such biomarkers can help stratify patients for personalized treatments, optimizing therapeutic outcomes and minimizing unnecessary toxicity. This advancement could enhance efficacy in glioma management, addressing a critical unmet need in neuro-oncology.